World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
77
Citations
33154
World Ranking
1322
National Ranking
39

Medicine

D-Index
77
Citations
33402
World Ranking
18260
National Ranking
231

Nathan Clumeck publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Nathan Clumeck sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 465 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Nathan Clumeck D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Nathan Clumeck sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 77 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Nathan Clumeck is affiliated with the Université Libre de Bruxelles in Belgium. Their research primarily focuses on medicine, with particular attention to infectious diseases, pediatrics, perinatology and child health, pulmonary and respiratory medicine, clinical biochemistry, and hepatology.

The main topics Nathan Clumeck explores include:

  • SARS-CoV-2 and COVID-19 Research
  • SARS-CoV-2 detection and testing
  • Infection Control and Ventilation
  • Metabolism and Genetic Disorders
  • Prenatal Substance Exposure Effects
  • Pharmacological Effects and Toxicity Studies
  • Hepatitis C virus research

Recent publications by Nathan Clumeck cover various aspects of infectious diseases and associated clinical outcomes. These papers are:

  • "Dynamics of SARS-CoV-2 RT-PCR positivity and seroprevalence among high-risk healthcare workers and hospital staff," 2020, Journal of Hospital Infection
  • "Observational cohort study of rilpivirine (RPV) utilization in Europe," 2022, AIDS Research and Therapy
  • "Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons," 2020, Open Forum Infectious Diseases
  • "Circulating HBV RNA and hepatitis B core-related antigen as determinants of HBsAg loss in persons with HIV in Europe," 2025, JHEP Reports

The scientist regularly publishes in journals such as the Journal of Hospital Infection, AIDS Research and Therapy, Open Forum Infectious Diseases, and JHEP Reports.

Collaborations with frequent co-authors are notable in Nathan Clumeck's work, including partnerships with:

  • Işık Somuncu Johansen
  • David Jilich
  • Inka Aho
  • Lars Peters
  • Christoph Stephan

Best Publications

  • Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection

    Richard K. Sterling;Eduardo Lissen;Eduardo Lissen;Nathan Clumeck;Ricard Sola

  • Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection : a case control study

    Daniel D. Murray;Kazuo Suzuki;Matthew Law;Jonel Trebicka

  • CD4+ count-guided interruption of antiretroviral treatment.

    Wafaa El-Sadr;Wafaa El-Sadr;Jens D Lundgren;James Neaton;Fred Gordin

  • Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

    Sharon L. Walmsley;Antonio Antela;Nathan Clumeck;Dan Duiculescu

  • Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

    Roy M. Gulick;Jacob Lalezari;James Goodrich;Nathan Clumeck

  • Acquired Immunodeficiency Syndrome in Rwanda

    Philippe Van De Perre;Philippe Lepage;Philippe Kestelyn;AntonC. Hekker

  • European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults

    N Clumeck;A Pozniak;F Raffi

  • Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.

    Alfredo Alberti;Nathan Clumeck;Simon Collins;Wolfram Gerlich

  • Treatment of Toxoplasmic Encephalitis in Patients with AIDS: A Randomized Trial Comparing Pyrimethamine plus Clindamycin to Pyrimethamine plus Sulfadiazine

    B Dannemann;J A McCutchan;D Israelski;D Antoniskis

  • Isolation of aids virus from cell-free breast milk of three healthy virus carriers

    L. Thiry;S. Sprecher-Goldberger;T. Jonckheer;J. Levy

  • Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study

    Antonella Castagna;Franco Maggiolo;Giovanni Penco;David Wright

  • Acquired Immunodeficiency Syndrome in African Patients

    Clumeck N;Sonnet J;Taelman H;Mascart-Lemone F

  • Comparison of Atovaquone (566C80) with Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients with AIDS

    Walter W. Hughes;Gifford G. Leoung;Françoise F. Kramer;Samuel S.A. Bozzette

  • An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

    Gilles Darcis;Anna Kula;Sophie Bouchat;Koh Fujinaga

  • A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection

    Sabine Kinloch De Loës;Bernard J. Hirschel;Bruno Hoen;David A. Cooper

  • Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study

    Amanda Mocroft;Andrew N. Phillips;Jose Gatell;Bruno Ledergerber

  • Pyrimethamine-Clindamycin vs. Pyrimethamine-Sulfadiazine as Acute and Long-Term Therapy for Toxoplasmic Encephalitis in Patients with AIDS

    C Katlama;S De Wit;E O'Doherty;M Van Glabeke

  • Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

    David A Cooper;Jayvant Heera;James Goodrich;Margaret Tawadrous

  • Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

    Sophie Reuse;Miriam Calao;Kabamba Kabeya;Allan Guiguen

  • Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

    John Gregson;Michele Tang;Nicaise Ndembi;Raph L Hamers

  • Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter

    David A. Cooper;Jose M. Gatell;Susanne Kroon;Nathan Clumeck

  • Treatment of Toxoplasmic Encephalitis in Patients with AIDS

    Brian Dannemann;J. Allen McCutchan;Dennis Israelski;Diane Antoniskis

Frequent Co-Authors

Stéphane De Wit
Stéphane De Wit Université Libre de Bruxelles
Jens D. Lundgren
Jens D. Lundgren Rigshospitalet
Christine Katlama
Christine Katlama Sorbonne University
Adriano Lazzarin
Adriano Lazzarin Vita-Salute San Raffaele University
José M. Gatell
José M. Gatell University of Barcelona
Andrew N. Phillips
Andrew N. Phillips University College London
Jan Gerstoft
Jan Gerstoft Rigshospitalet
David A. Cooper
David A. Cooper University of New South Wales
Andrzej Horban
Andrzej Horban Medical University of Warsaw
Peter Reiss
Peter Reiss University of Amsterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in expanding their career options beyond traditional microbiology roles, several online programs offer valuable pathways in health and medical fields. Exploring the best online cahiim accredited health information management degree programs can prepare graduates for managing healthcare data and improving patient outcomes through effective information systems.

Certain certifications can also enhance your profile quickly, such as the fast online medical billing and coding certification programs, which are designed for rapid completion and help you enter the administrative side of medical services. These roles often intersect with public health and clinical microbiology when dealing with healthcare facilities.

Moreover, if you’re exploring broader options within healthcare, there are a variety of online healthcare programs that cover diverse disciplines, ranging from nursing to specialized medical sciences. This flexibility supports professionals aiming to diversify their expertise or pursue interdisciplinary careers that include microbiology insights.

Finally, public health is a critical area for microbiologists interested in community health impact. Many students benefit from enrolling in online mph programs easy to get into, which provide practical knowledge in epidemiology and disease control, complementing microbiology studies and opening doors to leadership roles in health organizations.

Best Scientists Citing Nathan Clumeck

Trending Scientists

Recently Published Articles